207_Combined course Presentations

RTOG 0617 – Conclusions

 “ Positive” of RTOG 0617

• Excellent median survival of 28.7 months in the 60-Gy study arms when

compared with prior cooperative group studies in stage III NSCLC.

• May reflect PET scan use for staging (used in ~ 90% of pts)

 “ Negative” of RTOG 0617

• 74 Gy radiation with concurrent CT was not better than 60 Gy for patients with

stage III NSCLC, and might be potentially harmful.

• Addition of Cetuximab to concurrent CR-RT and consolidation treatment

provided no benefit in OS for these patients, but increased overall grade 3-5

toxicity (85% vs 69%, p < 0.0001)